Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Estradiol + Dydrogesteron, ATC G03FA14 für die Zeit 01.04.2026 - 31.03.2028 (zzgl. V.-Option 1x12 Monate)

Section 130a, paragraph 8, SGB V allows health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned active substance Estradiol + Dydrogesteron, ATC G03FA14, the DAK-Gesundheit intends to conclude rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical rebate contracts. A rebate contract under the authorisation model for the aforementioned active substance will come into force for the first time on 01.04.2026 and will end on 31.03.2028 (plus extension option 1x12 months). It will end automatically with the entry into force of the exclusive contract, regardless.